JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


The Journal of Nuclear Medicine Vol. 30 No. 4 474-480
© 1989 by Society of Nuclear Medicine
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Moyes, J. S. E.
Right arrow Articles by McElwain, T. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moyes, J. S. E.
Right arrow Articles by McElwain, T. J.

Quantitative Study of Radioiodinated Metaiodobenzylguanidine Uptake in Children with Neuroblastoma: Correlation with Tumor Histopathology

Judy S. E. Moyes, John W. Babich, Richard Carter, Simon T. Meller, Meena Agrawal and Timothy J. McElwain

Departments of Paediatric Oncology, Physics and Pathology, and Section of Medicine, The Royal Marsden Hospital, Sutton
Institute of Cancer Research, Sutton
Department of Surgery, Queen Mary's Hospital for Children, Carshalton, Surrey, UK

Correspondence: For reprints contact: Judy Moyes, MD, Dept. of Paediatrics, The Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, UK.

ABSTRACT

Six children with neuroblastoma and one with ganglioneuroma received [125I] metaiodobenzylguanidine (MIBG) before major surgery. Uptake of [125I]MIBG in the excised tissues was measured by scintillation counting, and the material was submitted for histopathology. The ranges of uptake of [125I]MIBG, expressed as percent of the injected dose per gram of tissue, were as follows: for neuroblastoma 0.0013–0.071, for ganglioneuroma 0.0017–0.0028, and for non-neoplastic control tissues 0.0002–0.011. The quantitative uptake of [125I]MIBG by neuroblastoma varied between different patients and between different parts of individual tumors. The more undifferentiated tumors took up more [125I]MIBG and may be more likely to respond to targeted radiotherapy with MIBG.




This article has been cited by other articles:


Home page
Arch. Dis. Child.Home page
S. MELLER
Targeted radiotherapy for neuroblastoma
Arch. Dis. Child., November 1, 1997; 77(5): 389 - 392.
[Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 1989 by the Society of Nuclear Medicine.